由于流感病毒RT期刊论文SR电子T1机械循环支持难治性心源性休克病毒相关性心肌炎JF欧洲呼吸杂志JO欧元呼吸杂志FD欧洲呼吸学会SP 2000925 DO 10.1183 / 13993003.00925-2020 A1 Sieweke，扬Thorben A1阿金，Muharrem188bet官网地址A1 Stetskamp，塞巴斯蒂安A1里勒，基督教A1 Jonigk，丹尼A1 Flierl，乌尔里克A1普费弗，托比亚斯乔纳森·赫希A1，A1瓦伦丁Dutzmann，约亨A1 Hoeper，马吕斯M. A1库恩基督教A1 Bauersachs，约翰A1舍费尔，安德烈YR 2020 UL//www.qdcxjkg.com/content/early/2020/05/07/13993003.00925-2020.abstract AB背景在患者与难治性心源性休克（RCS）复杂流感相关心肌炎有机械循环支持匮乏的证据（MCS）。我们试图使用组合的静脉 - 动脉体外膜肺氧合（VA-ECMO）调查MCS的影响，并在RCS微轴流泵复杂流感相关myocarditis.Methods这是从单个中心汉诺威心脏负载的预期和观测分析注册表从最近两次大流行流感季节（HACURE）。我们分析了患者的验证流感病毒感染相关的心肌炎住进了我们的MCS ICU RCS复杂。Subsequently, we performed a propensity score matched analysis to patients with acute myocardial infarction complicated by rCS and non-ischemic cardiomyopathy related rCS.Results We describe a series of seven patients with rCS complicating influenza-related myocarditis (mean age: 56±10 years, 58% males, Influenza A/B n=2/5). No patient had been vaccinated prior to the influenza season. MCS was provided using combined VA-ECMO and Impella. In two patients with out-of-hospital cardiac arrest VA-ECMO had been implanted for extracorporeal-cardiopulmonary resuscitation. All patients died within 18 days after hospital admission. By propensity score-based comparison to patients with myocardial infarction- or non-ischemic cardiomyopathy related rCS with combined MCS, 30-day mortality was significantly higher in influenza-related rCS.Conclusion Despite initial stabilisation with combined MCS in patients with rCS complicating influenza-related myocarditis, the detrimental course of shock could not be stopped and all patients died. Potentially, influenza virus infection critically affects other organs besides the heart leading to irreversible end-organ damage, which MCS cannot compensate and, therefore, resulted in a devastating outcome.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Sieweke reports other from ABIOMED, outside the submitted work.Conflict of interest: Dr. Akin has nothing to disclose.Conflict of interest: Mr. Stetskamp has nothing to disclose.Conflict of interest: Dr. Riehle reports other from Abiomed, outside the submitted work.Conflict of interest: Dr. Jonigk has nothing to disclose.Conflict of interest: Dr. Flierl has nothing to disclose.Conflict of interest: Dr. Pfeffer has nothing to disclose.Conflict of interest: Dr. Hirsch has nothing to disclose.Conflict of interest: Dr. Dutzmann has nothing to disclose.Conflict of interest: Dr. Höper reports personal fees from Actelion, Bayer, MSD, and Pfizer, outside the submitted work.Conflict of interest: Dr. Kühn has nothing to disclose.Conflict of interest: Dr. Bauersachs reports personal fees from Novartis, personal fees from BMS, personal fees from Pfizer, grants and personal fees from Vifor, personal fees from Bayer, personal fees from Servier, grants and personal fees from CvRX, personal fees from MSD, personal fees from Boehringer Ingelheim, personal fees from Astra Zeneca, grants and personal fees from Abiomed, personal fees from Abbott, personal fees from Medtronic, personal fees from Daiichi Sankyo, grants and personal fees from Zoll, outside the submitted work.Conflict of interest: Dr. Schäfer reports grants and personal fees from Abiomed, during the conduct of the study.